rivaroxaban
rivaroxaban
Overview
Rivaroxaban is an oral anticoagulant used in the prevention and treatment of thromboembolic disease. It belongs to the class of direct oral anticoagulants (DOACs) and acts by selectively inhibiting factor Xa, a key enzyme in the coagulation cascade that promotes thrombin generation and fibrin clot formation. By reducing factor Xa activity, rivaroxaban lowers the blood’s ability to clot and is used in a range of cardiovascular and thrombosis-related settings.
Clinically, rivaroxaban is relevant in conditions such as non-valvular atrial fibrillation, venous thromboembolism, and selected high-risk cardiovascular populations where anticoagulation is indicated. Its use is also closely tied to bleeding management and reversal strategies, including the use of andexanet alfa in severe hemorrhage. In recent research, rivaroxaban has also been studied alongside apixaban and aspirin in comparative effectiveness, dual-pathway inhibition, and pharmacokinetic interaction contexts.
Focus of Latest Publications
Recent publications on rivaroxaban have focused on its role in anticoagulation across cardiovascular, peripheral vascular, oncology, and pharmacokinetic settings, as well as on reversal strategies for bleeding. In atrial fibrillation and chronic coronary syndrome, rivaroxaban was evaluated alongside other antithrombotic approaches in comparative and guideline-oriented analyses. One study assessed the cost-effectiveness of apixaban versus warfarin, dabigatran, edoxaban, and rivaroxaban for non-valvular atrial fibrillation from the Belgian payer perspective, while a COMPASS substudy examined the net clinical benefit of extended dual pathway inhibition with aspirin and rivaroxaban in chronic coronary syndrome according to the 2024 ESC high-risk criteria.
Several publications addressed rivaroxaban use after vascular intervention and in real-world practice. A retrospective cohort study was designed to evaluate low-dose rivaroxaban, reflecting the VOYAGER PAD regimen of 2.5 mg twice daily, following peripheral vascular intervention for peripheral artery disease, with the abstract noting that the clinical trial evidence showed reduced major adverse limb events but increased bleeding. Another real-world study specifically investigated the effectiveness and safety of low-dose rivaroxaban after peripheral arterial endovascular revascularization. These reports indicate continued interest in how trial-based rivaroxaban strategies translate into routine care.
Other studies examined rivaroxaban in drug interaction and formulation contexts. In healthy volunteers, sotorasib was tested for its effect on the pharmacokinetics of a single 20 mg dose of rivaroxaban, and the study found no clinically relevant pharmacokinetic interaction, with both drugs well tolerated. Separately, a modeling study used published plasma concentration-time profiles of rivaroxaban orally disintegrating tablets to derive absorption-delay functions and predict delayed absorption under fed conditions without water; the framework reproduced observed rivaroxaban ODT profiles and yielded predicted Tmax and Cmax values consistent with reported data.
Rivaroxaban also appeared in publications related to anticoagulant reversal and bleeding management. One report described emergency reversal of rivaroxaban with andexanet alfa in a child with hemorrhagic brain metastasis from Wilms tumor, highlighting the lack of pediatric reversal guidelines. Another study examined trends and variation in the use of andexanet alfa across NHS trusts in England, noting that NICE had recommended it as an option for life-threatening gastrointestinal bleeding in patients taking apixaban or rivaroxaban, while guidance for intracranial hemorrhage remained unresolved. Together, these publications reflect ongoing work on rivaroxaban’s comparative effectiveness, real-world use, pharmacokinetics, and reversal in urgent bleeding scenarios.